Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB5 | P28074 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 16/20 | 0.36 |
| ▸ | CTSL | P07711 | 10/20 | 0.36 |
| ▸ | CTSS | P25774 | 9/20 | 0.36 |
| ▸ | CTSB | P07858 | 4/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13677144 | 0.91 | PSMB5 (0.38) | PSMB5CTSKCTSLCTSSCTSB | |
| SCHEMBL4456153 | 0.91 | PSMB5 (0.38) | PSMB5CTSKCTSLCTSSCTSB | |
| SCHEMBL13677137 | 0.84 | CTSK (0.40) | PSMB5CTSKCTSLCTSSCTSB | |
| SCHEMBL4457952 | 0.84 | CTSK (0.40) | PSMB5CTSKCTSLCTSSCTSB | |
| SCHEMBL13677153 | 0.83 | PSMB5 (0.37) | PSMB5CTSKCTSLCTSSCTSB | |
| SCHEMBL13677150 | 0.83 | PSMB5 (0.36) | PSMB5CTSKCTSLCTSSCTSB | |
| SCHEMBL13677149 | 0.83 | CTSK (0.38) | PSMB5CTSKCTSLCTSSCTSB | |
| SCHEMBL4444637 | 0.82 | ACE2 (0.43) | PSMB5CTSKCTSLCTSSCTSB | |
| SCHEMBL13677145 | 0.82 | ACE2 (0.43) | PSMB5CTSKCTSLCTSSCTSB | |
| SCHEMBL13677143 | 0.77 | PSMB5 (0.38) | PSMB5CTSKCTSLCTSSCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090247471-A1 | INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES | AMURA THERAPEUTICS LTD. (GB) | 2009-10-01 | — | — | US | disclosed |
| US-20090247471-A1 | INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES | AMURA THERAPEUTICS LTD. (GB) | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247471-A1 | INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES | CPN1, CTRL, CPA1 | PSMB5 131/4885CTSK 45/4885CTSL 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.